Caribou Biosciences (CRBU) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to -$29.4 million.
- Caribou Biosciences' Income towards Parent Company rose 23.11% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of -$149.1 million for FY2024, which is 46.08% down from last year.
- Latest data reveals that Caribou Biosciences reported Income towards Parent Company of -$29.4 million as of Q3 2025, which was up 38.21% from -$47.6 million recorded in Q2 2025.
- Caribou Biosciences' Income towards Parent Company's 5-year high stood at -$13.2 million during Q1 2021, with a 5-year trough of -$47.6 million in Q2 2025.
- Moreover, its 3-year median value for Income towards Parent Company was -$38.2 million (2024), whereas its average is -$36.6 million.
- As far as peak fluctuations go, Caribou Biosciences' Income towards Parent Company crashed by 664.48% in 2021, and later spiked by 44.86% in 2023.
- Quarterly analysis of 5 years shows Caribou Biosciences' Income towards Parent Company stood at -$18.5 million in 2021, then tumbled by 65.47% to -$30.6 million in 2022, then declined by 22.45% to -$37.4 million in 2023, then declined by 3.83% to -$38.9 million in 2024, then grew by 23.11% to -$29.4 million in 2025.
- Its Income towards Parent Company was -$29.4 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$42.9 million in Q1 2025.